公开(公告)号：US20240294884A1

公开(公告)日：2024-09-05

申请号：US18663981

申请日：2024-05-14

Applicant: Janssen Biotech, Inc.

Inventor： Ricardo ATTAR ,  Jason DEHART ,  Selina KHAN ,  Vinod KRISHNA ,  Jenifer LUM ,  Christian MAINE ,  Barbara SANDERS ,  Manuel Alejandro SEPULVEDA ,  Patrick WILKINSON ,  Roland ZAHN

IPC: C12N7/00 ,  A61K39/00 ,  A61K45/06 ,  C12N15/86

CPC classification number: C12N7/00 ,  A61K45/06 ,  C12N15/86 ,  A61K2039/505 ,  C12N2750/14111

Abstract: Provided are vaccines, polypeptides and polynucleotides based on mutant CALR and JAK2 sequences, vectors, host cells, viruses, and methods of making and using them. The disclosure also provides methods of inducing an immune response and methods of treating, preventing, reducing a risk of onset or delaying the onset of a clinical condition characterized by an expression of JAK2V617F or CALR exon 9 mutant, or both JAK2V617F and CALR exon 9 mutant, wherein the method comprises a plurality of administrations of any of the compositions comprising polynucleotides, polypeptides or vectors disclosed herein.

公开(公告)号：US20230079750A1

公开(公告)日：2023-03-16

申请号：US17712661

申请日：2022-04-04

Applicant: Janssen Biotech, Inc.

Inventor： Rebecca HANSON ,  Vinod KRISHNA ,  Manuel Alejandro SEPULVEDA ,  Patrick WILKINSON

IPC: C07K14/725 ,  C12N15/86

Abstract: Described herein are T-cell receptors (TCRs) that bind to CALR or JAK2 antigens. Also described are T-cell receptors (TCRs), polynucleotides, vectors that encode the TCRs, and cells comprising the TCRs, and methods of treatment.

公开(公告)号：US20230285548A1

公开(公告)日：2023-09-14

申请号：US18080639

申请日：2022-12-13

Applicant: Janssen Biotech, Inc.

Inventor： Patrick WILKINSON ,  Manuel Alejandro Sepulveda ,  Charles George Drake ,  Derick Siegel

IPC: A61K39/235 ,  A61K39/285 ,  A61K39/395 ,  A61K45/06

CPC classification number: A61K39/235 ,  A61K39/285 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505

Abstract: Disclosed herein are methods of treating or preventing a myeloproliferative disease, a cancer, or a cardiovascular disease, and methods of inducing an immune response, in a subject having a JAK2V617F substitution and/or a CALR exon 9 mutation.

公开(公告)号：US20230190903A1

公开(公告)日：2023-06-22

申请号：US18080634

申请日：2022-12-13

Applicant: Janssen Biotech, Inc.

Inventor： Patrick WILKINSON ,  Manuel Alejandro SEPULVEDA ,  Charles George DRAKE ,  Derick Siegel

IPC: A61K39/00 ,  A61K39/395 ,  A61P35/00

CPC classification number: A61K39/001193 ,  A61K39/3955 ,  A61P35/00 ,  A61K2039/5256 ,  A61K2039/70 ,  A61K2039/545

Abstract: Disclosed herein are methods of treating or preventing prostate cancer in a subject, the methods comprising administering to the subject a treatment regimen comprising two or more vaccines comprising a great ape adenovirus serotype 20 (GAd20) virus that, in turn, comprises a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 1 and one or more vaccines comprising a Modified Vaccinia Ankara (MVA) virus that, in turn, comprises a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 3 to thereby treat or prevent the prostate cancer.

公开(公告)号：US20210222133A1

公开(公告)日：2021-07-22

申请号：US17097458

申请日：2020-11-13

Applicant: Janssen Biotech, Inc.

Inventor： Ricardo ATTAR ,  Jason DEHART ,  Selina KHAN ,  Vinod KRISHNA ,  Jenifer LUM ,  Christian MAINE ,  Barbara SANDERS ,  Manuel Alejandro SEPULVEDA ,  Patrick WILKINSON ,  Roland ZAHN

IPC: C12N7/00 ,  C12N15/86 ,  A61K45/06

Abstract: Provided are vaccines, polypeptides and polynucleotides based on mutant CALR and JAK2 sequences, vectors, host cells, viruses, and methods of making and using them. The disclosure also provides methods of inducing an immune response and methods of treating, preventing, reducing a risk of onset or delaying the onset of a clinical condition characterized by an expression of JAK2V617F or CALR exon 9 mutant, or both JAK2V617F and CALR exon 9 mutant, wherein the method comprises a plurality of administrations of any of the compositions comprising polynucleotides, polypeptides or vectors disclosed herein.